Cipla is expected to report net profit at Rs 414.7 crore in October-December quarter, up 26.5 percent from Rs 327.85 crore in corresponding quarter last fiscal. According to a CNBC-TV18 poll, revenue may climb 23.4 percent to Rs 3412.5 crore in Q3 versus Rs 2765.5 crore year-on-year.
During the period, EBITDA may rise 25.5 percent to Rs 694.8 crore against Rs 553.8 crore while operating profit margins are seen at 20.4 percent versus 20.03 percent (year-on-year).
As per analysts polled by CNBC-TV18, US business may be driven by continued supplies of Nexium API. Non-ARV (Anti-retroviral) tender business in South Africa & Germany is likely to steady. However, currency depriciation like South African Rand may impact ex-US export markets.
Analysts will keep an eye on better offtake of respiratory drugs in EU post deployment of front-end in key EU markets.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
